Coronavirus Pandemic
Tianjin CanSino Biologics (HK: 6185) published positive results from a China Phase I trial of its COVID-19 vaccine in the prestigious British journal, The Lancet. In the study, the Ad5 vectored COVID-19 vaccine was immunogenic at 28 days post-vaccination with only mild or moderate side effects. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and specific T-cell responses were noted from day 14 post-vaccination. The vaccine, which was based on CanSino's approved Ebola vaccine, has already started a Phase II trial.
Moderna (MRNA), a Boston-area mRNA company, reported positive